Replies to post #29 on Equity Field Notes from temporal sources

[DanWebzster]

DMCAF

CEO owns IP to ony recombinant of Kalikrein (KLK1) (does company own IP?)

Lead program is Ph2 study of efficacy of KLK1 in patients with acute ischemic stroke. first patient enrolled 2/18.

Ph1 demonstrated superiority over competing chinese treatment

TAM "could " exceed 2Bn